Brooks Laboratories Ltd

  • BSE Code : 533543
  • NSE Symbol : BROOKS
  • ISIN : INE650L01011
  • Industry :PHARMACEUTICALS - INDIAN - BULK DRUGS & FORMLN

up-arrow 44.53 7.42(19.99%)

Open Price ()

38.98

Prev. Close ()

37.11

Volume (No’s)

83,311

Market Cap ()

109.32

Low Price ()

38.98

High Price ()

44.53

 

Board Meetings

Start Date End Date Purpose
29-Jan-2026 06-Feb-2026 Brooks Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 06/02/2026 inter alia to consider and approve and take on record the Unaudited Financial Results (Standalone and Consolidated) for the quarter and nine months ended December 31 2025 along with Limited Review Report issued by the Statutory Auditors of the Company thereon. Outcome of the Board Meeting held on Friday, 6th February 2026. (As Per BSE Announcement Dated on: 06/02/2026)
07-Nov-2025 14-Nov-2025 Brooks Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/11/2025 inter alia to consider and approve and take on record the Unaudited Financial Results (Standalone and Consolidated) for the quarter and half year ended September 30 2025 along with Limited Review Report of the Statutory Auditors of the Company thereon. Outcome of the Board Meeting held on Friday, 14th November 2025. (As per BSE Announcement dated on: 14.11.2025)
07-Aug-2025 13-Aug-2025 Brooks Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/08/2025 inter alia to consider and approve the Unaudited Financial Results (Standalone and Consolidated) of The Company for the Quarter Ended June 30 2025. Unaudited Financial Results and Limited Review for the quarter ended June 30, 2025 (As Per BSE Announcement Dated on: 13.08.2025)
23-May-2025 28-May-2025 Brooks Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 28/05/2025 inter alia to consider and approve the Audited standalone and consolidated financial results of the Company for the quarter and year ended 31st March 2025. Outcome of Board Meeting held on Wednesday, 28th May 2025 Pursuant to provision of Regulation 30 and 33 and otjer applicable provision of SEBI(LODR) 2015 to consider, approved and taken on record the matter mentioned in the attachment. (As Per BSE Announcement dated on 28.05.2025)
10-Feb-2025 13-Feb-2025 BROOKS LABORATORIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/02/2025 inter alia to consider and approve Unaudited Financial Results (Standalone and Consolidated) for the quarter and nine months ended December 31 2024 along with Limited Review Report of Statutory Auditors of the Company thereon pursuant to Regulation 33 of the Securities and Exchange Board of India (Listing Obligation and Disclosure Requirements) Regulations 2015. Outcome of Board Meeting under Regulation 30 & Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015 (As per BSE Announcement Dated on 13/02/2025) Revision of the outcome of the Board Meeting held on 13th February 2025. (As Per Bse Announcement Dated on 25.02.2025)

Copyright © 2026 Arihant Capital Markets Ltd. All rights Reserved.

Designed, Developed and Content powered by CMOTS InfoTech (ISO 9001:2015 & ISO/IEC 27001:2022 Certified)

x
  • QR-CodeNew